07/10/2026 US FDA grants two breakthrough therapy designations to AbbVie’s c-Met ADC Temab-A in CRC and NSCLC US FDA approves tucatinib-based maintenance regimen for HER2-positive Breast Cancer US FDA grants two breakthrough therapy designations to AbbVie’s c-Met ADC Temab-A in CRC and NSCLC (Ref) AbbVie announced that the US FDA has granted two Breakthrough Therapy Designations (BTDs) to c-Met-targeted antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A/ABBV-400

05/10/2026 In Phase 3 EPCORE DLBCL-2 study, epcoritamab + R-CHOP significantly improved PFS in newly diagnosed DLBCL In Phase 3 EPCORE DLBCL-2 study, epcoritamab + R-CHOP significantly improved PFS in newly diagnosed DLBCL (Ref) Genmab and AbbVie reported positive Phase 3 EPCORE DLBCL-2 results, evaluating fixed treatment duration epcoritamab (T-cell engaging bispecific antibody) in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vinc

03/09/2026 Phase 3 CERVINO interim analysis shows etentamig significantly improves ORR and PFS in RRMM, with IDMC recommending study unblinding Phase 3 CERVINO interim analysis shows etentamig significantly improves ORR and PFS in RRMM, with IDMC recommending study unblinding (Ref) AbbVie reported positive topline results from the Phase 3 CERVINO trial, demonstrating that etentamig (BCMA x CD3 bispecific T-cell engager) significantly improved response rates and progression-fr

23/07/2026 Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma Epcoritamab Phase 3 DLBCL trial failed to meet OS endpoint Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma (Ref) Johnson & Johnson announced positive topline results from the Phase 3 MonumenTAL-6 trial of TECVAYLI and TALVEY combinations in relapsed/refractory multiple myeloma patients. MonumenTAL-6 trial evaluated TECVAYLI® (tec

29/06/2026 Genmab & AbbVie's epcoritamab + lenalidomide combination meets primary endpoint of PFS in Phase 3 DLBCL trial Samsung Bioepis’ Keytruda biosimilar SB27 demonstrates Phase 1 and Phase 3 equivalence in NSCLC trials MHRA validates Eisai and Nuvation Bio's taletrectinib MAA in UK, expanding ROS1+ NSCLC access Genmab & AbbVie's epcoritamab + lenalidomide combination meets primary endpoint of PFS in Phase 3 DLBCL trial (Ref) Genmab announced positive topline results from

12/06/2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC AbbVie's Venetoclax Shows Sustained 9-Year Efficacy in First-Line CLL at EHA 2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC (Ref) The Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in relapsed/second-line metastatic small cell lung cancer (SCLC), did not meet its primary endpoint of overall survival (OS) fo

20/02/2026 The combination of venetoclax and acalabrutinib has been approved by the US FDA for CLL The combination of venetoclax and acalabrutinib has been approved by the US FDA for CLL (Ref) The US FDA has approved a sNDA for Abbvie & Genentech's venetoclax (BCL-2 inhibitor) + AstraZeneca's acalabrutinib (BTK inhibitor) for the treatment of previously untreated adult patients with CLL The approval is supported by data from the Phase 3 AMPLIFY trial Dr. Brian Koffman, co-fou

18/11/2025 AbbVie and Genmab's epcoritamab + rituximab + lenalidomide received FDA approval for R/R FL (Ref) The US FDA granted approval to AbbVie and Genmab's epcoritamab (bispecific CD20-directed CD3 T-cell engager) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the Phase 3 EPCORE FL-1 trial of the combo vs rituximab and lenalidomide Lorenzo Falchi, M.D., Ly

30/09/2025 Umoja Biopharma's UB-VV111 in vivo CAR T cell therapy received the FDA fast track designation for B-Cell Malignancies (Ref) The US FDA granted the fast track designation to Umoja Biopharma's UB-VV111 (off-the-shelf drug product that generates CD19-directed CAR T cells in vivo) for the treatment of relapsed/refractory Large B-cell Lymphoma following two or more lines of prior therapy and relapsed/refractory Chronic Lymphocytic Leukemia following two or more lines of

07/08/2025 ProteinQure's PQ203 received the Fast track designation for TNBC (Ref) The US FDA granted the Fast Track designation to ProteinQure's PQ203 (SORT1 targeting peptide drug conjugate) for the treatment of patients with triple negative breast cancer. ProteinQure also received regulatory clearance from both the US FDA and Health Canada to initiate a Phase 1 trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of PQ203 The Phase 1 stud

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases. Despite development of novel treatment options and targeted therapeutics, the 5-year survival rate in adult population is quite low, indicating towards a huge unmet need in AML treatment space. The current infographic concisely highlights the key treatment options for AML and some of the emerging therapeutic stratagems.

Since March is Multiple Myeloma Awareness Month, we at Oncofocus have created an informative infographic highlighting the current treatment options and emerging therapies for Multiple Myeloma.